Bone Biologics (OTC:BBLG) Shares Down 4.5% – What’s Next?

Bone Biologics Co. (OTC:BBLG) fell 4.5% during mid-day trading on Wednesday . The company traded as low as $1.25 and last traded at $1.26. 21,851 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,505,719 shares. The stock had previously closed at $1.32.

Bone Biologics Stock Down 4.5 %

The business’s 50-day moving average price is $1.64 and its 200-day moving average price is $1.57. The firm has a market capitalization of $3.10 million, a PE ratio of -0.03 and a beta of 0.45.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.